A $50.0M seed round is an unusually large bet for a biotech startup, and K2 Therapeutics just closed one backed solely by MPM BioImpact. The company, founded by experienced drug developers, is positioning itself as a global hunter for innovative assets, unconstrained by modality or geography.
K2’s pitch is straightforward: find the most promising first- and best-in-class candidates anywhere in the world, then apply a disciplined development approach to turn them into medicines with broad patient impact. The single-investor seed round suggests MPM is placing a concentrated wager on that thesis, giving K2 the runway to start translating its search into a pipeline.





.png&w=3840&q=75)











